InvestorsHub Logo
Followers 30
Posts 5248
Boards Moderated 0
Alias Born 10/16/2012

Re: pphmtoolong post# 111990

Thursday, 02/14/2013 12:44:31 PM

Thursday, February 14, 2013 12:44:31 PM

Post# of 345999
It may have been this part of Shan's statement that caused the concern:

"In light of this data, as well as other recent developments in the treatment of pancreatic cancer, we are actively evaluating the next steps for advancing the bavituximab pancreatic program," said Joseph Shan.

One can read between the lines and conclude that Peregrine is shelving the Bavi Pancreatic pursuit. I may be wrong - I hope I am - but that part of the PR is what stuck out to me. Some companies leave it vague when concluding a study.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News